NCT05812781

A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome

A Phase 2A, Single-Arm Study to Evaluate the Safety and Clinical Activity of VTX2735 in Participants With Cryopyrin-Associated Periodic Syndrome (CAPS)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 7 (actual)
• Sponsor: Zomagen Biosciences Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a study to understand if taking VTX2735 is safe and effective in participants diagnosed with Cryopyrin-Associated Period Syndrome (CAPS). Approximately 10 patients will take VTX2735 Dose A or VTX2735 Dose B. The study consists of a screening/washout period of up to 28 weeks, a 2 week treatment period, a treatment withdrawal period of up to 2 weeks, another 2 week treatment period, and a 4 week follow up period. The maximum length of treatment is 4 weeks.

Conditions

• Cryopyrin Associated Periodic Syndrome

Interventions

Type	Name	Description
DRUG	VTX2735	Dose A
DRUG	VTX2735	Dose B

Timeline

• Start date: 2023-03-18
• Primary completion: 2024-03-06
• Completion: 2024-03-06
• First posted: 2023-04-14
• Last updated: 2025-03-10

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study